Transcription of Module 2.5 Clinical Overview
{{id}} {{{paragraph}}}
Example: bachelor of science
Module 2.5 Clinical Overview
CONFIDENTIALM odule Clinical Overview1 Module OverviewCopyright 2012 ViiV Healthcare and the GlaxoSmithKline group of companies. All rights reserved. Unauthorizedcopying or use of this information is Clinical Overview2 TABLE OF PRODUCT DEVELOPMENT Therapies and its Unmet Clinical Indication and Development with Good Clinical Practice (GCP)..132. Overview OF Overview OF , Distribution, Metabolism and Elimination of and in Healthy Subjects and Target Patient of Dolutegravir PK in Special with Hepatitis B or of Dolutegravir on thePharmacokinetics of Other of Other Agents on the Pharmacokinetics of Dolutegravir and Dose of DTG on Cardiac of DTG on Renal Pharmacodynamic Relationships and Definition of No Effect Boundaries .. Relationship for Combination Relationship for Safety ..30 CONFIDENTIALM odule Clinical of No Effect Boundaries of Alteration in DTG Pharmacology Overview OF of Patient Populations in Pivotal and Supportive Efficacy for Dose Selection in Clinical ve/ART-Experienced (INI-Na ve) (INI-Resistant) Trial Methodology and Design (Pivotal Efficacy Study Designs).
CONFIDENTIAL Module 2.5 Clinical Overview 6 ABBREVIATIONS 3TC lamivudine ABC abacavir AE Adverse event AIDS Acquired immunodeficiency syndrome ALT Alanine aminotransferase
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: